Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
7 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: Interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up.
J Am Acad Dermatol. 2023 Dec;89(6):1149-1158. doi: 10.1016/j.jaad.2023.07.1024. Epub 2023 Aug 6.
J Am Acad Dermatol. 2023.
PMID: 37553030
Free article.
Clinical Trial.
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data.
Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, Gisondi P, Sinvhal R, Armstrong AW.
Shear NH, et al. Among authors: sinvhal r.
J Am Acad Dermatol. 2021 Sep;85(3):572-581. doi: 10.1016/j.jaad.2021.02.057. Epub 2021 Feb 22.
J Am Acad Dermatol. 2021.
PMID: 33631216
Free article.
Item in Clipboard
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up.
Papp KA, Lebwohl MG, Puig L, Ohtsuki M, Beissert S, Zeng J, Rubant S, Sinvhal R, Zhao Y, Soliman AM, Alperovich G, Leonardi C.
Papp KA, et al. Among authors: sinvhal r.
Br J Dermatol. 2021 Dec;185(6):1135-1145. doi: 10.1111/bjd.20595. Epub 2021 Sep 21.
Br J Dermatol. 2021.
PMID: 34157132
Free PMC article.
Clinical Trial.
Item in Clipboard
Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, Blauvelt A, Kaplan B, Shah M, Zhao Y, Sinvhal R, Reich K.
Gordon KB, et al. Among authors: sinvhal r.
Br J Dermatol. 2022 Mar;186(3):466-475. doi: 10.1111/bjd.20818. Epub 2021 Nov 24.
Br J Dermatol. 2022.
PMID: 34652810
Free PMC article.
Item in Clipboard
Letter to the editor concerning the article: 'Potential cerebrovascular accident signal for risankizumab: A disproportionality analysis of the FDA adverse event reporting system (FAERS)'.
Sinvhal R, Krueger WS, Kilpatrick RD, Coppola D.
Sinvhal R, et al.
Br J Clin Pharmacol. 2023 Aug;89(8):2639-2641. doi: 10.1111/bcp.15746. Epub 2023 Apr 27.
Br J Clin Pharmacol. 2023.
PMID: 37114281
No abstract available.
Item in Clipboard
Enhanced external counterpulsation for refractory angina pectoris.
Sinvhal RM, Gowda RM, Khan IA.
Sinvhal RM, et al.
Heart. 2003 Aug;89(8):830-3. doi: 10.1136/heart.89.8.830.
Heart. 2003.
PMID: 12860848
Free PMC article.
Item in Clipboard
Confounding issues in COPD risk study?
Sinvhal R, Tosiello L, Cable G.
Sinvhal R, et al.
Chest. 2003 Jan;123(1):307; author reply 307-8. doi: 10.1378/chest.123.1.307.
Chest. 2003.
PMID: 12527640
No abstract available.
Item in Clipboard
Cite
Cite